Any new partner with the means to further the development of apabetalone would, I would think, want a significant ownership stake in RVX.  The only way to get that is by RVX either issuing new shares or by buying existing shares from current shareholders.  The price paid to Hepalink and Eastern, who currently collectively own approximately 65% of the company, for those shares will of course impact the value of all RVX shares.  So, if you presently have some 212M shares o/s and a new partner wants, say, a controlling interest of 115M shares without further dilution then they would have to pay HL and Eastern for those shares.  At, for example, $3/share it would cost them about $350M

In the absence of the above, I suppose a new partner could also opt for a preferred royalty on future sales of ABL, or some combination of the two.  We just don't know how a partnership deal will be structured, but it now seems certain that a deal is coming and we just have to wait and see what it looks like.